T-cell engagers

News

UK's Cytospire draws in $83m for new T-cell engager platform

Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.

News

UCB buys T-cell therapy biotech Candid for $2bn upfront

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

News

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

News

Ouro makes debut with $120m for autoimmune disease TCEs

Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.

UK's Cytospire draws in $83m for new T-cell engager platform

UCB buys T-cell therapy biotech Candid for $2bn upfront

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Kidney biotech R1's $78m debut, and other biofinancings

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Ouro makes debut with $120m for autoimmune disease TCEs

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

T-cell engagers

Editor's Picks